My ISA Watch List: GlaxoSmithKline plc, Diageo plc And PZ Cussons plc

Why I’m watching GaxoSmithKline plc (LON: GSK), Diageo plc (LON: DGE) and PZ Cussons plc (LON: PZC) for this year’s ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

From 6 April 2016, we get another ISA allowance of £15,240, and that’s a tax-free investment opportunity worth grabbing.

Leading with quality

I’m looking for firms that can pay a reliable and growing stream of dividends in the years to come. If the company has a quality business with strong cash flow, capital growth should follow. Expanding dividend payments and a rising share price mean a double win that should drive pleasing total returns.

Quality firms can go on my watch list waiting for a sensible entry point, such as during periods of general market weakness, or when a temporary issue knocks the firm’s share price.

Today’s focus is on GlaxoSmithKline (LSE: GSK), Diageo (LSE: DGE) and PZ Cussons (LSE: PZC). 

Defensive attributes

These firms attract because of their defensive qualities. GlaxoSmithKline, the pharmaceutical giant, trades in an industry characterised by consistent demand, and people often repeat-purchase the firm’s products. That set-up tends to generate reliable flows of cash for GlaxoSmithKline. Meanwhile, Diageo’s alcoholic drinks output also feeds into a consumer-driven market. People come back repeatedly for their favourite tipple and that translates into a reliable cash stream for Diageo.

PZ Cusson’s portfolio of consumable goods brands in the personal care, home care, beauty, food and nutrition markets is also a great cash generator. The common theme linking these three firms is that they all sell stuff that people need over and over again, profitably.

Outlooks

In February, GlaxoSmithKline’s chief executive said: “For 2016, we continue to expect core EPS percentage growth to reach double-digits on a constant currency basis, although we are also mindful that the macroeconomic and healthcare environment will continue to be challenging.”

Despite possible headwinds, GlaxoSmithKline looks set to lumber through 2016 and beyond. The firm announced a special dividend for 2015 and that strikes me as a good indicator that the firm remains in good health.

In January, Diageo’s chief executive said: “While trading conditions remain challenging in some markets, Diageo’s brands, capabilities in marketing and innovation and our route to consumer have proved resilient. I am confident that Diageo can deliver improved, sustained performance.”

Diageo’s top man is confident that the drinks provider can keep powering forward and so am I. The firm operates in an attractive industry and enjoys substantial economic moats with its popular brands.

Commenting on the firm’s interim results in January, PZ Cussons’ chairman said: These are a steady set of results in what have been challenging markets with overall revenue and profitability broadly flat versus the comparative period. We remain confident about the medium and long-term opportunities which should begin to materialise.”

I’m also confident that PZ Cussons’ business model will keep it afloat and steady in difficult times, and growing nicely in the good times.

All three of these firms operate good quality, cash-generating and enduring businesses, and because of that, their valuations tend to look a little pricey at times. However, buying on dips, down days and during times of general market malaise can be one way of building up a position in the longer-term growth stories on offer. That’s why I think they’re good candidates for my ISA watch list.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of PZ Cussons. The Motley Fool UK has recommended Diageo and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »